광역동 치료(PDT) 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of photodynamic therapy (PDT) Market

The global photodynamic therapy (PDT) market was valued at USD 2.03 billion in 2025 and is projected to grow to USD 2.18 billion in 2026, eventually reaching USD 4.03 billion by 2034, representing a robust CAGR of 7.97% during the forecast period. North America emerged as the leading regional market in 2025, capturing 37.02% of the global share, driven by the increasing prevalence of chronic diseases, growing patient admissions, and the strategic focus of key players on mergers, acquisitions, and product innovations.

Photodynamic therapy utilizes oxygen, light energy, and photosensitizing agents-either natural or synthetic-that become activated upon light exposure to treat chronic conditions such as cancer, psoriasis, and actinic keratosis. The rising prevalence of chronic disorders, particularly cancer, is driving higher diagnosis and treatment rates, thus fueling the adoption of advanced therapies like PDT.

Market Drivers

The increasing prevalence of chronic diseases is a major growth factor. In the U.S., approximately 1.96 million new cancer cases were projected in 2023, while over 8 million people are affected by psoriasis, reflecting rising demand for effective treatments. Technological advancements, including the integration of nanotechnology, such as quantum dots and biocompatible molecules, are improving PDT efficacy and patient outcomes. Collaborative efforts, such as Photonamic GmbH & Co KG partnering with Lumeda, Inc. in 2023 for lung cancer PDT trials, illustrate the ongoing innovation in the market.

Moreover, minimally invasive procedures are increasingly preferred, prompting key players to develop new photosensitizer drugs and advanced devices that target diseased cells precisely while minimizing harm to healthy tissue.

Market Restraints

Despite these advantages, limited patient awareness, especially in emerging markets, hinders market growth. High treatment costs, around USD 8,500 per PDT procedure, further constrain adoption. Additionally, the availability of alternative therapies reduces the urgency among patients to opt for PDT, particularly in regions with lower healthcare literacy.

Segmentation Analysis

By Product Type:

The PDT market is divided into photosensitizer drugs and photodynamic therapy devices. Photosensitizer drugs dominate with a 65.03% market share in 2026, driven by benefits such as minimal invasiveness and enhanced efficacy. Notable approvals include Bausch + Lomb and Modulight Corporation's VISUDYNE in February 2023. PDT devices, including laser and non-laser systems, are also expected to grow due to AI integration and advanced light sources.

By Application:

The cancer segment led with 54.63% market share in 2026, fueled by rising cancer prevalence and benefits like targeted therapy and reduced damage to healthy cells. Actinic keratosis, psoriasis, and acne segments are expected to grow steadily due to increasing patient awareness and demand for innovative therapies.

By End-User:

Hospitals accounted for the largest segment at 62.73% in 2026, supported by rising patient admissions, reimbursement policies, and increasing adoption of PDT in healthcare facilities. Specialty clinics and other end-users are also witnessing growth due to availability of novel drugs and devices.

Regional Insights

• North America: Valued at USD 0.75 billion in 2025, projected to reach USD 0.81 billion in 2026, with the U.S. market expected at USD 0.73 billion in 2026. Growth is driven by chronic disease prevalence and strategic activities by key players.
• Europe: Marketed at USD 0.58 billion in 2025, projected to reach USD 0.63 billion in 2026, with Germany at USD 0.21 billion and the U.K. at USD 0.15 billion in 2026. Actinic keratosis and other skin disorders drive adoption.
• Asia Pacific: Valued at USD 0.45 billion in 2025, expected at USD 0.48 billion in 2026, with Japan, China, and India contributing significantly due to aging populations and rising chronic disorders.
• Latin America & Middle East & Africa: Latin America was USD 0.15 billion in 2025, reaching USD 0.16 billion in 2026, and the Middle East & Africa contributed USD 0.09 billion in 2025, projected at USD 0.10 billion in 2026. Growth is driven by awareness and novel product launches.

Key Industry Players and Developments

The PDT market is consolidated, with key players like Biofrontera AG (Germany), Lumibird (France), Sun Pharmaceutical Industries Ltd. (India), Galderma (Switzerland), and Bausch + Lomb (Canada) leading. Recent developments include Biofrontera AG's RhodeXL lamp launch in June 2024, Galderma's collaboration with German Medical Engineering in February 2023, and Better Therapeutics' FDA approval for AspyreRx in July 2023.

Conclusion

The global photodynamic therapy market is poised for substantial growth between 2025 and 2034, fueled by rising chronic disease prevalence, technological advancements, and increasing adoption of minimally invasive procedures. While high costs and limited patient awareness pose challenges, strategic collaborations, innovative product launches, and regional expansion are expected to drive the market toward USD 4.03 billion by 2034.

Segmentation By Product Type

• Photosensitizer Drugs
  • Oral
  • Parenteral
• Photodynamic Therapy Devices
  • Laser
  • Non-Laser

By Application

• Cancer
• Actinic Keratosis
• Acne
• Psoriasis
• Others

By End-User

• Hospitals
• Specialty Clinics
• Others

By Region

• North America (By Product Type, Application, End-User, and Country)
  • U.S.
  • Canada
• Europe (By Product Type, Application, End-User, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, Application, End-User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, Application, End-User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, Application, End-User, and Country/Sub-region)
  • GCC South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disorders, Key Countries/Regions, 2025
• 4.2. Technological Advancements in Photodynamic Therapy Devices
• 4.3. New Product Launches
• 4.4. Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
• 4.5. Impact of COVID-19 on the Market

5. Global Photodynamic Therapy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Photosensitizer Drugs
    • 5.1.1.1. Oral
    • 5.1.1.2. Parenteral
  • 5.1.2. Photodynamic Therapy Devices
    • 5.1.2.1. Laser
    • 5.1.2.2. Non-Laser
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Cancer
  • 5.2.2. Actinic Keratosis
  • 5.2.3. Acne
  • 5.2.4. Psoriasis
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Photodynamic Therapy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Photosensitizer Drugs
    • 6.1.1.1. Oral
    • 6.1.1.2. Parenteral
  • 6.1.2. Photodynamic Therapy Devices
    • 6.1.2.1. Laser
    • 6.1.2.2. Non-Laser
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Cancer
  • 6.2.2. Actinic Keratosis
  • 6.2.3. Acne
  • 6.2.4. Psoriasis
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Photodynamic Therapy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Photosensitizer Drugs
    • 7.1.1.1. Oral
    • 7.1.1.2. Parenteral
  • 7.1.2. Photodynamic Therapy Devices
    • 7.1.2.1. Laser
    • 7.1.2.2. Non-Laser
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Cancer
  • 7.2.2. Actinic Keratosis
  • 7.2.3. Acne
  • 7.2.4. Psoriasis
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia pacific Photodynamic Therapy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Photosensitizer Drugs
    • 8.1.1.1. Oral
    • 8.1.1.2. Parenteral
  • 8.1.2. Photodynamic Therapy Devices
    • 8.1.2.1. Laser
    • 8.1.2.2. Non-Laser
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Cancer
  • 8.2.2. Actinic Keratosis
  • 8.2.3. Acne
  • 8.2.4. Psoriasis
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. Australia
  • 8.4.3. China
  • 8.4.4. India
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Photodynamic Therapy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Photosensitizer Drugs
    • 9.1.1.1. Oral
    • 9.1.1.2. Parenteral
  • 9.1.2. Photodynamic Therapy Devices
    • 9.1.2.1. Laser
    • 9.1.2.2. Non-Laser
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Cancer
  • 9.2.2. Actinic Keratosis
  • 9.2.3. Acne
  • 9.2.4. Psoriasis
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Photodynamic Therapy Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Photosensitizer Drugs
    • 10.1.1.1. Oral
    • 10.1.1.2. Parenteral
  • 10.1.2. Photodynamic Therapy Devices
    • 10.1.2.1. Laser
    • 10.1.2.2. Non-Laser
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Cancer
  • 10.2.2. Actinic Keratosis
  • 10.2.3. Acne
  • 10.2.4. Psoriasis
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals
  • 10.3.2. Specialty Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. BIOFRONTERRA AG
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. LUMIBIRD
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Sun Pharmaceutical Industries Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. GALDERMA
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Bausch + Lomb
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Luzitin, S.A.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Novartis AG
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Modulight Corporation
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Theralase Technologies Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)